The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection ...

Among patients with uncontrolled hypertension, the investigational drug lorundrostat brought a significant reduction in blood pressure at 12 weeks compared with placebo, according to a study presented ...

People taking an oral formulation of the glucagon-like peptide-1 (GLP-1) agonist semaglutide were 14% less likely than those taking a placebo to ...

Background Cardiac surgery carries a heightened risk of bradyarrhythmias, but current permanent pacemaker (PPM) implantation ...

1 Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, UK 2 School of Sport and Exercise Science, University of Bedfordshire, Bedford, UK 3 ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...

RAHWAY, N.J. - Merck & Co., Inc. (NYSE: MRK), a global healthcare leader, has announced an exclusive licensing agreement with Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma), a company ...

Impax Global Opportunities Fund underperformed the benchmark during the last quarter. Its overweight position in Health Care ...

Orlistat, an antiobesity drug with well-documented efficacy in weight reduction and maintenance, has beneficial effects on metabolic variables. It reduces the incidence of Type 2 diabetes in ...